Anti-CCR8 Antibodies Therapeutic Agents Patent Application
Summary
USPTO published patent application US20260098096A1 for anti-CCR8 antigen binding proteins and fragments for detection and therapy of various conditions, including cancer. The application was filed September 21, 2023, by inventor Remy Michel Robert. CCR8 is a G-protein coupled receptor implicated in tumor immunosuppression.
What changed
USPTO published patent application US20260098096A1 covering anti-CCR8 antigen binding proteins and fragments for therapeutic and diagnostic use. The application includes claims to CCR8-binding antibodies, antibody fragments, and methods of treating conditions associated with CCR8 expression, particularly cancer. The patent contains CPC classifications spanning antibody therapeutics (C07K 16/2866) and anticancer applications (A61P 35/00).
Biotechnology and pharmaceutical companies developing CCR8-targeted immunotherapies should monitor this patent's prosecution and potential claims scope. The patent provides intellectual property protection for CCR8 antibody developers and may influence freedom-to-operate analyses for cancer immunotherapy programs.
What to do next
- Monitor for updates
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTI-CCR8 ANTIBODIES
Application US20260098096A1 Kind: A1 Apr 09, 2026
Inventors
Remy Michel ROBERT
Abstract
The invention relates to antigen binding proteins and related fragments thereof for binding to CCR8, to production of said antigen binding proteins and fragments and to use of said antigen binding proteins and fragments for detection and therapy of various conditions.
CPC Classifications
C07K 16/2866 A61P 35/00 A61K 2039/505 C07K 2317/24 C07K 2317/31 C07K 2317/524 C07K 2317/526 C07K 2317/565 C07K 2317/567 C07K 2317/622 C07K 2317/732
Filing Date
2023-09-21
Application No.
19113897
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.